Assessment of Functional Status of Human Leukocyte Antigen Class I Genes in Cancer Tissues in the Context of Personalized Neoantigen Peptide Vaccine Immunotherapy
JCO Clinical Cancer Informatics · 2025
DOI: 10.1200/cci-24-00174 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Clinical Cancer Informatics, 2025. Verfasst von Vijay G Padul und 6 weiteren Autor:innen. Beteiligte Einrichtung: Rhenix Lifesciences, Hyderabad, India. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Cancer Vaccines, Vaccines, Subunit. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Accurate human leukocyte antigen (HLA) typing is an essential step for designing peptide vaccines used in the personalized neoantigen peptide vaccine immunotherapy (PNPVT) in patients with cancer. The reasons for variation in the patient response to PNPVT are yet unknown. One of the reasons could be the somatic changes in the HLA genes in the cancer cells. The objective of the present research was to analyze the somatic status of HLA class I genes in cancer tissue through integrative genomic analysis and to identify high-confidence subset of potentially functional cancer somatic HLA class I genotype relevant to PNPVT. PATIENTS AND METHODS Whole-exome (paired tumor-normal) and RNAseq (tumor) paired-end sequencing data from 24 patients with cancer were used for the analysis. The genotyping of HLA class I was performed using four HLA typing software tools. To assess the functional status of HLA class I genes in the cancer tissue, we analyzed somatic mutation, HLA gene loss of heterozygosity, and chromosome 6 copy loss status in cancer exome data. RESULTS Somatic mutations in HLA genes were detected in the tumor data of five patients, and somatic HLA gene loss of heterozygosity was identified in the tumor data of five patients. Complete or partial chromosome 6 copy loss was detected in eight patient samples. CONCLUSION The results indicate that HLA class I genes may get affected by somatic changes in cancer tissue, and assessment of the somatic status of the HLA genotype should be performed in the cancer tissues. The results provide robust rational for removal of mutated or lost HLAs from the personalized neoantigen peptide prediction pipeline to potentially increase the efficacy of the PNPVT. Further functional studies are needed to assess the impact of HLA gene mutations/loss on PNPVT outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Rhenix Lifesciences, Hyderabad, India.
- CureScience, San Diego, CA.
- Medicine, Pan American Cancer Treatment Center, Tijuana, Mexico.
- Neurology, Pan American Cancer Treatment Center, Tijuana, Mexico.
- Department of Translational Neurosciences, Pacific Neuroscience Institute and Saint John's Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA.
ORCID-Profile: Vijay G Padul, Santosh Kesari, Shashanka Ashili
Zitieren
APA
Padul, V. G., Biswas, N., Gill, M., Perez, J. A., Lopez, J. J., Kesari, S., & Ashili, S. (2025). Assessment of Functional Status of Human Leukocyte Antigen Class I Genes in Cancer Tissues in the Context of Personalized Neoantigen Peptide Vaccine Immunotherapy. JCO Clinical Cancer Informatics. https://doi.org/10.1200/cci-24-00174
Vancouver
Padul VG, Biswas N, Gill M, Perez JA, Lopez JJ, Kesari S, et al. Assessment of Functional Status of Human Leukocyte Antigen Class I Genes in Cancer Tissues in the Context of Personalized Neoantigen Peptide Vaccine Immunotherapy. JCO Clinical Cancer Informatics. 2025. doi:10.1200/cci-24-00174
BibTeX
@article{Padul2025,
author = {Padul, Vijay G and Biswas, Nupur and Gill, Mini and Perez, Jesus A and Lopez, Javier J and Kesari, Santosh and Ashili, Shashanka},
title = {Assessment of Functional Status of Human Leukocyte Antigen Class I Genes in Cancer Tissues in the Context of Personalized Neoantigen Peptide Vaccine Immunotherapy},
journal = {JCO Clinical Cancer Informatics},
year = {2025},
doi = {10.1200/cci-24-00174}
}
EUVIMED